has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug conjugate (ADC ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα ...

The company also has a follow-up FRα-targeting ADC – IMGN-151 – which is in phase 1. GlobalData has predicted that, with its first-to-market advantage, Elahere could generate $2.8 billion in ...

Elahere secured full approval from the US Food and Drug Administration last year. Credit: © AbbVie. US-based pharmaceutical company AbbVie has reported the final ...

US-based pharmaceutical company AbbVie has reported the final analysis from the Phase III MIRASOL trial, which assessed its antibody-drug conjugate (ADC) Elahere against chemotherapy for treating ...

Elahere (mirvetuximab soravtansine-gynx) is a brand-name injection that’s prescribed for certain types of cancer. Elahere has interactions with some other drugs. Examples include certain ...

Genmab acquired the biotech for $1.8 billion last year, securing rights to a challenger to AbbVie’s Elahere. AbbVie alleges that ProfoundBio initially failed to produce a viable ADC pipeline and ...

Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared ... drug conjugate (ADC) comprising a folate ...

AbbVie recently announced the final analysis from the Phase III MIRASOL trial, showcasing the effectiveness of Elahere for treating platinum-resistant ovarian cancer. Elahere demonstrated a ...

Elahere showed superior efficacy over chemotherapy in progression-free survival, objective response rate, and overall survival in the MIRASOL trial. The treatment reduced the risk of tumor progression ...